400 related articles for article (PubMed ID: 16891898)
1. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
Pahlka RB; Sonnad JR
Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
[TBL] [Abstract][Full Text] [Related]
2. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.
Courbon F; Caselles O; Zerdoud S; Duthil P; Regis H; Berry I; Caron P
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):363-70. PubMed ID: 17043635
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy.
Kaptein EM; Levenson H; Siegel ME; Gadallah M; Akmal M
J Clin Endocrinol Metab; 2000 Sep; 85(9):3058-64. PubMed ID: 10999786
[TBL] [Abstract][Full Text] [Related]
5. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
Modarresifar H; Almodovar S; Bass WB; Ojha B
Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
7. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
8. Management of Patients with Renal Failure Undergoing Dialysis During
Vermandel M; Debruyne P; Beron A; Devos L; Talbot A; Legrand JF; Provôt F; Lion G
J Nucl Med; 2020 Aug; 61(8):1161-1170. PubMed ID: 31924716
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
11. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C
J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193
[TBL] [Abstract][Full Text] [Related]
12. Individualized dosimetry in the management of metastatic differentiated thyroid cancer.
Chiesa C; Castellani MR; Vellani C; Orunesu E; Negri A; Azzeroni R; Botta F; Maccauro M; Aliberti G; Seregni E; Lassmann M; Bombardieri E
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):546-61. PubMed ID: 19910908
[TBL] [Abstract][Full Text] [Related]
13. Glycophorin A as a biological dosimeter for radiation dose to the bone marrow from iodine-131.
Jensen RH; Reynolds JC; Robbins J; Bigbee WL; Grant SG; Langlois RG; Pineda JD; Lee T; Barker WC
Radiat Res; 1997 Jun; 147(6):747-52. PubMed ID: 9189175
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure.
Driedger AA; Quirk S; McDonald TJ; Ledger S; Gray D; Wall W; Yoo J
Clin Nucl Med; 2006 Aug; 31(8):454-7. PubMed ID: 16855429
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
17. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).
Bianchi L; Baroli A; Lomuscio G; Pedrazzini L; Pepe A; Pozzi L; Chiesa C
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):515-21. PubMed ID: 23358404
[TBL] [Abstract][Full Text] [Related]
19. Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy.
Murcutt G; Edwards J; Boakye J; Davenport A
Kidney Int; 2008 Jun; 73(11):1316-9. PubMed ID: 18354377
[TBL] [Abstract][Full Text] [Related]
20. 131I treatment of thyroid papillary carcinoma in a patient with renal failure.
Morrish DW; Filipow LJ; McEwan AJ; Schmidt R; Murland KR; von Westarp C; Betcher KB
Cancer; 1990 Dec; 66(12):2509-13. PubMed ID: 2249192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
